JPRN-UMIN000018554Recruiting未知
Clinical Trial of Sofosbuvir/Ribavirin for HCV Genotype 2-infected Japanese Patients - Oral regimen for Genotype 2
Gunma University and affiliated hospitals0 sites50 target enrollmentStarted: August 5, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have allergy to sofosbuvir or ribavirin Patients with renal dysfunction Patients with less than 12 g/dl hemoglobin Patients expecting a child and have a possibility of pregnancy or who are breast-feeding Patients taking contraindicated drug Patients whom the doctor in attendance judged as inappropriate
Investigators
Similar Trials
Completed
Not Applicable
Prospective study of Sofosbuvir/Ribavirin for HCV genotype 2 infected Japanese patientsGenotype 2 infected chronic liver diseasesJPRN-UMIN000019399Osaka City University and affiliated hospitals250
Completed
Phase 3
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV InfectionHepatitis CNCT01896193Gilead Sciences127
Completed
Phase 2
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian PatientsChronic Hepatitis C Virus InfectionNCT04385407Beni-Suef University203
Completed
Phase 2
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV PatientsHepatitis CNCT01054729Gilead Sciences64
Completed
Phase 3
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)Chronic Hepatitis CNCT01604850Gilead Sciences202